Enhancing the antitumor effects of sorafenib in sorafenib-resistant hepatocellular carcinoma cells by regulating Keap1/Nrf2-associated ferroptosis and EMT. The gene discussed is NFE2L2; the disease is hepatocellular carcinoma.